Human p53 restores DNA synthesis control in fission yeast

Biological Chemistry

Volumn 378, Issue 11, 1997, Pages 1361-1371

  Bureik, Matthias ^a   Jungbluth, Andreas ^a   Drescher, Rudolf ^a   Wagner, Peter ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CDC25C; DNA synthesis control; Fission yeast; p53

Indexed keywords

PROTEIN P53;

ARTICLE; DNA SYNTHESIS; GENE MUTATION; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TRANSACTIVATION; TRANSCRIPTION REGULATION; ULTRAVIOLET IRRADIATION; YEAST;

SCHIZOSACCHAROMYCES POMBE;

EID: 0030681064     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/bchm.1997.378.11.1361     Document Type: Article

References (84)

1. Appel, K., Schneider, E., Wagner, P., Höog, J.-O., Karlsson, C., and Montenarh, M. (1994). A new 42 kDa protein binding to the growth suppressor protein p53. Int. J. Oncol. 5, 667-673.
2. Appel, K., Wagner, P., Boldyreff, B., Issinger, O.G., and Montenarh, M. (1995). Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory β - subunit of protein kinase CK2. Oncogene 11, 1971-1978.
3. Bischoff, J.R., Casso, D., and Beach, D. (1992). Human p53 inhibits growth in Schizosaccharomyces pombe. Mol. Cell. Biol. 12, 1405-1411.
4. Broek, D., Bartlett, R., Crawford, K., and Nurse, P. (1991). Involvement of p34cdc2 in establishing the dependency of S phase on mitosis. Nature 349, 388-393.
5. Chen, J., Jackson, P.K., Kirschner, M.W., and Dutta, A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374, 386-388.
6. Chen, J.J., Peters, R., Saha, P., Lee, P., Theodoras, A., Pagano, M., Wagner, G., and Dutta, A. (1996). A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res. 24, 1727-1733.
7. D'Urso, G., and Nurse, P. (1995). Checkpoints in the cell cycle of fission yeast. Curr. Opin. Genet. Dev. 5, 12-16.
8. Demetrick, D.J., and Beach, D.H. (1993). Chromosome mapping of human CDC25A and CDC25B phosphatases. Genomics 18, 144-147.
9. Dobner, T., Horikoshi, N., Rubenwolf, S., and Shenk, T. (1996). Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272, 1470-1473.
10. Ducommun, B., Brambilla, P., and Draetta, G. (1991). Mutations at sites involved in Suc1 binding inactivate Cdc2. Mol. Cell Biol. 11, 6177-6184.
11. Dunphy, W.G., and Kumagai, A. (1991). The cdc25 protein contains an intrinsic phosphatase activity. Cell 67, 189-196.
12. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
13. 1 arrest and apoptosis. Cancer Res. 54, 1169-1174.
14. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86, 8763-8767.
15. Enoch, T., and Nurse, P. (1990). Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication. Cell 60, 665-673.
16. Enoch, T., and Nurse, P. (1991). Coupling M phase and S phase: Controls maintaining the dependence of mitosis on chromosome replication. Cell 65, 921-923.
17. Enoch, T., Carr, A.M., and Nurse, P. (1992). Fission yeast genes involved in coupling mitosis to completion of DNA replication. Genes Dev. 6, 2035-2046.
18. Fields, S., and Jang, S.K. (1990). Presence of a potent transcription activating sequence in the p53 protein. Science 249, 1046-1049.
19. Finlay, C.A., Hinds, P.W., and Levine, A.J. (1989). The p53 protooncogene can act as a suppressor of transformation. Cell 57, 1083-1093.
20. Forsburg, S.L., and Nurse, P. (1991). Cell cycle regulation in the yeasts Saccharomyces cerevisiae and Schizosaccharomyces pombe. Annu. Rev. Cell Biol. 7, 227-256.
21. Galaktionov, K., Lee, A.K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., and Beach, D. (1995). CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577.
22. Gautier, J., Solomon, M.J., Booher, R.N., Bazan, J.F., and Kirschner, M.W. (1991). cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67, 197-211.
23. Girard, F., Strausfeld, U., Cavadore, J.-C., Russell, P., Fernandez, A., and Lamb, N.J.C. (1992). cdc25 is a nuclear protein expressed constitutively throughout the cell cycle in nontransformed mammalian cells. J. Cell Biol. 118, 785-794.
24. + protein kinase regulates entry into mitosis. Nature 342, 39-45.
25. Greenblatt, M.S., Bennett, W.P., Hollstein, M., and Harris, C.C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
26. Grimm, C., Kohli, J., Murray, J., and Maundrell, K. (1988). Genetic engineering of Schizosaccharomyces pombe: a system for gene disruption and replacement using the ura4 gene as a selectable marker. Mol. Gen. Genet. 215, 81-86.
27. Harlow, E., Crawford, L.V., Pim, D.C., and Williamson, N.M. (1981). Monoclonal antibodies specific for the SV40 tumor antigens. J. Virol. 39, 861-869.
28. Hartwell, L.H., and Weinert, T.A. (1989). Checkpoints: Controls that ensure the order of cell cycle events. Science 246, 629-634.
29. Hartwell, L.H., and Kastan, M.B. (1994). Cell cycle control and cancer. Science 266, 1821-1828.
30. Harvey, D.M., and Levine, A. J. (1991). p53 Alteration is a common event in the spontaneous immortalization of primary BALB/c murineembryofibroblasts. Genes Dev. 5, 2375-2385.
31. Herrmann, C.P.E., Kraiss, S., and Montenarh, M. (1991). Association of casein kinase II with immunopurified p53. Oncogene 6, 877-884.
32. Hupp, T.R., Meek, D.W., Midgley, C.A., and Lane, D.P. (1992). Regulation of the specific DNA binding function of p53. Cell 71, 875-886.
33. Ishioka, C., Frebourg, T., Van, Y.-X., Vidal, M., Friend, S.H., Schmidt, S., and Iggo, R. (1993). Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genet. 5, 124-129.
34. Jacks, T., and Weinberg, R.A. (1996). Cell-cycle control and its watchman. Nature 387, 643-644.
35. Jinno, S., Suto, K., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. (1994). CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13, 1549-1556.
36. Kastan, M.B. (1993). P53: A determinant of the cell cylce response to DNA damage. Adv. Exp. Med. Biol. 339, 291-293.
37. Kraiss, S., Barnekow, A., and Montenarh, M. (1990). Protein kinase activity associated with immunopurified p53 protein. Oncogene 5, 845-855.
38. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V., and Kastan, M.B. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495.
39. Labib, K., and Moreno, S. (1996). rum1: A CDK inhibitor regulating G1 progression in fission yeast. Trends Cell Biol. 6, 62-66.
40. Lane, D.P., and Benchimol, S. (1990). p53: Oncogene or anti-oncogene. Genes Dev. 4, 1-8.
41. Lee, J.M., and Bernstein, A. (1993). p53 Mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90, 5742-5746.
42. Levine, A.J., Momand, J., and Finlay, C.A. (1991). The p53 tumour suppressor gene. Nature 351, 453-456.
43. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., and Jacks, T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
44. Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.P., Jr., Nelson, C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., Tainsky, M.A., and Friend, S.H. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238.
45. rum1 cdk inhibitor. EMBO J. 15, 839-849.
46. Maundrell, K. (1990). nmt1 of fission yeast. J. Biol. Chem. 265, 10857-10864.
47. Mercer, W.E., Shields, M.T., Lin, D., Appella, E., and Ullrich, S.J. (1991). Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA 88, 1958-1962.
48. cdc2 in transformed cells. EMBO J. 9, 2885-2889.
49. + gene. Nature 367, 236-242.
50. Murray, A.W. (1992). Creative blocks: Cell-cycle checkpoints and feedback controls. Nature 359, 599-604.
51. Murray, A.W. (1995). The genetics of cell cycle checkpoints. Curr. Opin. Genet. Dev. 5, 5-11.
52. + gene occurs in humans and is highly expressed in some cancer cells. New Biol. 3, 959-968.
53. Nakazawa, H., English, D., Randell, P.L., Nakazawa, K., Martel, N., Armstrong, B.K., and Yamasaki, H. (1994). UV and skin cancer: Specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA 91, 360-364.
54. Nigro, J.M., Sikorski, R., Reed, S.I., and Vogelstein, B. (1992). Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae. Mol. Cell. Biol. 12, 1357-1365.
55. Norbury, C., and Nurse, P. (1992). Animal cell cycles and their control. Annu. Rev. Biochem. 61, 441-470.
56. Nurse, P. (1975). Genetic control of cell size at cell division in yeast. Nature 256, 547-551.
57. Nurse, P. (1990). Universal control mechanism regulating onset of M-Phase. Nature 344, 503-507.
58. cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes. EMBO J. 11, 1763-1772.
59. Oren, M. (1992). The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev. 11, 141-148.
60. Ory, K., Legros, Y., Auguin, C., and Soussi, T. (1994). Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13, 3496-3504.
61. Phipps, J., Nasim, A., and Miller, D.R. (1985). Recovery, repair, and mutagenesis in Schizosaccharomyces pombe. Adv. Genet. 23, 1-72.
62. Roussou, I., and Draetta, G. (1994). The Schizosaccharomyces pombe casein kinase II α and β subunits: Evolutionary conservation and positive role of the β subunit. Mol. Cell. Biol. 14, 576-586.
63. + functions as an inducer in the mitotic control of fission yeast. Cell 45, 145-153.
64. +, a gene encoding a protein kinase homolog. Cell 49, 559-567.
65. Russo, G.L., Vandenberg, M.T., Yu, I.Y., Bae, Y., Franza, B.R., and Marshak, D.R. (1992). Casein kinase II phosphorylated p34cdc2 kinase in G1 phase of the HeLa cell division cycle. J. Biol. Chem. 267, 20317-20325.
66. Sadhu, K., Reed, S.I., Richardson, H., and Russell, P. (1991). Human homology of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA 87, 5139-5143.
67. Schärer, E., and Iggo, R. (1992). Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res. 20, 1539-1545.
68. Schmitt, H.D., Wagner, P., Pfaff, E., and Gallwitz, D. (1986). The ras-related YPT1 gene product in yeast: AGTP-binding protein that might be involved in microtubule organization. Cell 47, 401-412.
69. Selter, H., and Montenarh, M. (1994). The emerging picture of p53. Int. J. Biochem. 26, 145-154.
70. Sheldrick, K.S., and Carr, A.M. (1993). Feedback controls and G2 checkpoints: Fission yeast as a model system. BioEssays 15, 775-782.
71. Strausfeld, U., Labbe, J.C., Fesquet, D., Cavadore, J.C., Picard, A., Sadhu, K., Russell, P., and Doree, M. (1991). Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351, 242-245.
72. cdc2 in mammalian cells: Implications for cell cycle control and oncogenesis. Oncogene 5, 795-802.
73. Thut, C.J., Chen, J., Klemm, R., and Tjian, R. (1996). p53 transcriptional activation mediated by coactivators TAF40 and TAF60. Science 267, 100-104.
74. Tommasino, M., and Maundrell, K. (1991). Uptake of thiamine by Schizosaccharomyces pombe and its effect as a transcriptional regulator of thiamine-sensitive genes. Curr. Genet. 20, 63-66.
75. Wagner, P. (1994). p53 forms tight complexes with tms1 of fission yeast. Int. J. Oncol. 4, 987-992.
76. cdc2 reversible growth arrest in fission yeast. Oncogene 6, 1539-1547.
77. Wagner, P., Hengst, L., and Gallwitz, D. (1992). YPT proteins in yeast. Methods Enzymol. 219, 369-387.
78. Wagner, P., Grimaldi, M., and Jenkins, J.R. (1993). Putative dehydrogenase tms1 suppresses growth arrest induced by a p53 tumour mutant in fission yeast. Eur. J. Biochem. 217, 731-736.
79. Wagner, P., Appel, K., Issinger, O.G., and Montenarh, M. (1994). On the interaction of p53 with casein kinase II. Int. J. Oncol. 4, 491-498.
80. Wagner, P., Fuchs, A., and Nastainczyk, W. (1995a). Definition of the p53 binding site on the tms1 protein from fission yeast. Int. J. Oncol. 7, 171-175.
81. Wagner, P., Fuchs, A., Prowald, A., Montenarh, M., and Nastainczyk, W. (1995b). Precise mapping of the tms1 binding site on p53. FEBS Lett. 377, 155-158.
82. Wagner, P., Hoever, M., Appel, K., Knöchel, W., and Montenarh, M. (1995c). Fission yeast tms1 protein abrogates normal development in Xenopus laevis embryos. Roux's Arch. Dev. Biol. 204, 198-202.
83. Waldman, T., Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1996). Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381, 713-716.
84. Wang, Y., and Prives, C. (1995). Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376, 88-91.